

Mark L Chiu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/622301/publications.pdf>

Version: 2024-02-01

27
papers

1,018
citations

623734

14
h-index

610901

24
g-index

28
all docs

28
docs citations

28
times ranked

1295
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibody Structure and Function: The Basis for Engineering Therapeutics. <i>Antibodies</i> , 2019, 8, 55.	2.5	273
2	A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. <i>Cancer Research</i> , 2016, 76, 3942-3953.	0.9	165
3	The Effect of Ionic Liquids on Protein Crystallization and X-ray Diffraction Resolution. <i>Crystal Growth and Design</i> , 2009, 9, 3463-3469.	3.0	82
4	Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. <i>Journal of Biological Chemistry</i> , 2021, 296, 100641.	3.4	80
5	Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells. <i>MAbs</i> , 2017, 9, 114-126.	5.2	58
6	Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody. <i>Journal of Biological Chemistry</i> , 2016, 291, 27134-27146.	3.4	51
7	Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor- c-MET Bispecific Antibody. <i>Journal of Biological Chemistry</i> , 2015, 290, 24689-24704.	3.4	40
8	Over-Expression, Solubilization, and Purification of G Protein-Coupled Receptors for Structural Biology. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2008, 11, 439-462.	1.1	38
9	Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody. <i>MAbs</i> , 2016, 8, 551-561.	5.2	35
10	Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune Functionality. <i>Antibodies</i> , 2017, 6, 12.	2.5	31
11	Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization. <i>MAbs</i> , 2017, 9, 1129-1142.	5.2	25
12	Human IgG subclass cross-species reactivity to mouse and cynomolgus monkey Fc γ 3 receptors. <i>Immunology Letters</i> , 2018, 197, 1-8.	2.5	22
13	Rapid Purification of Human Bispecific Antibodies via Selective Modulation of Protein A Binding. <i>Scientific Reports</i> , 2017, 7, 15521.	3.3	16
14	An efficient process of generating bispecific antibodies via controlled Fab-arm exchange using culture supernatants. <i>Protein Expression and Purification</i> , 2016, 121, 133-140.	1.3	14
15	Unique pharmacology of a novel allosteric agonist/sensitizer insulin receptor monoclonal antibody. <i>Molecular Metabolism</i> , 2018, 10, 87-99.	6.5	14
16	Raman spectroscopy characterization of antibody phases in serum. <i>MAbs</i> , 2014, 6, 1509-1517.	5.2	12
17	Fc γ RII-binding Centyrins mediate agonism and antibody-dependent cellular phagocytosis when fused to an anti-OX40 antibody. <i>MAbs</i> , 2018, 10, 463-475.	5.2	12
18	Influence of the bispecific antibody IgG subclass on T cell redirection. <i>MAbs</i> , 2019, 11, 1012-1024.	5.2	11

#	ARTICLE	IF	CITATIONS
19	Kinetic mechanism of controlled Fab-arm exchange for the formation of bispecific immunoglobulin G1 antibodies. <i>Journal of Biological Chemistry</i> , 2018, 293, 651-661.	3.4	10
20	Novel Monoclonal Antibody Is an Allosteric Insulin Receptor Antagonist That Induces Insulin Resistance. <i>Diabetes</i> , 2017, 66, 206-217.	0.6	9
21	Modulation of protein A binding allows single-step purification of mouse bispecific antibodies that retain FcRn binding. <i>MABs</i> , 2017, 9, 1306-1316.	5.2	7
22	Introduction to Membrane Proteins. <i>Current Protocols in Protein Science</i> , 2002, 29, Unit 29.1.	2.8	5
23	Developability Assessment of a Proposed NIST Monoclonal Antibody. <i>ACS Symposium Series</i> , 2015, , 329-355.	0.5	5
24	Abstract DDT01-03: Discovery and preclinical pharmacology of JNJ-61186372: A novel bispecific antibody targeting EGFR and cMET. , 2014, , .		2
25	Toward Crystallization of G Protein-Coupled Receptors. <i>Drug Discovery Series</i> , 2005, , 271-296.	0.1	1
26	Membrane Proteins. <i>Current Protocols in Protein Science</i> , 2012, 69, 29.0.1.	2.8	0
27	Abstract A11: Activity of a bispecific antibody targeting EGFR and cMet with enhanced Fc effector function in EGFR mutant setting with cMet pathway activation. , 2015, , .		0